Stone Files SC 13D for Scinai Immunotherapeutics

TL;DR

**Stone ups stake in Scinai!** 📈

AI Summary

On March 12, 2024, Daniel E. Stone filed an SC 13D form regarding Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.). The filing indicates a change in beneficial ownership, though specific details on the number of shares or dollar amounts are not provided in this excerpt. The company is involved in the biological products sector.

Why It Matters

This filing signals a potential shift in control or significant stake acquisition in Scinai Immunotherapeutics, which could impact the company's strategic direction and stock performance.

Risk Assessment

Risk Level: medium — SC 13D filings often indicate significant stake changes, which can lead to volatility and uncertainty for existing shareholders.

Key Players & Entities

• Scinai Immunotherapeutics Ltd. (company) — Subject company
• BiondVax Pharmaceuticals Ltd. (company) — Former company name
• Daniel E. Stone (person) — Filing party
• David Tang (person) — Copy to contact
• Dorsey & Whitney LLP (company) — Legal counsel

FAQ

From the Filing

0000912282-24-000243.txt : 20240312 0000912282-24-000243.hdr.sgml : 20240312 20240312161713 ACCESSION NUMBER: 0000912282-24-000243 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20240312 DATE AS OF CHANGE: 20240312 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-89384 FILM NUMBER: 24742292 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: STONE DANIEL E. CENTRAL INDEX KEY: 0001948744 ORGANIZATION NAME: FILING VALUES: FORM TYPE: SC 13D MAIL ADDRESS: STREET 1: 1200 BRICKELL AVENUE, #1470 CITY: MIAMI STATE: FL ZIP: 33131 SC 13D 1 sc13d.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 SCINAI IMMUNOTHERAPEUTICS LTD. (formerly BioindVax Pharmaceuticals Ltd.) (Name of Issuer)   Ordinary ADS Shares (Title of Class of Securities) 09073Q204 (CUSIP Number) Daniel E. Stone 1200 Brickell Avenue, #1470 Miami, FL 33131 Copy to: David Tang Dorsey & Whitney LLP 51 West 52 nd Street New York, NY 10029                                                                                   (212) 415-9379 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) March 12, 2024 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  X Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 09073Q204 1 NAMES OF REPORTING PERSONS Daniel E. Stone 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)   ☐ (b)   ☐ 3 SEC USE ONLY 4 SOURCE OF FUNDS (SEE INSTRUCTIONS) PF 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2 ☐ Not Applicable 6 CITIZENSHIP OR PLACE OF ORGANIZATION United States NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 7 SOLE VOTING POWER 624,000 8 SHARED VOTING POWER 0 9 SOLE DISPOSI